LONDON, Sept 22 (Reuters) - A new drug to treat a rare
inherited bone disorder that was developed by Alexion
Pharmaceuticals and could cost up to 1.5 million pounds
($2 million) a year per patient has been cleared for limited use
by Britain's health cost watchdog.
Read more
No comments:
Post a Comment